Form 4: Bluebird Bio Director Michael Cloonan Acquires 37,350 Shares of Common Stock

Director Michael Cloonan acquired 37,350 shares of Bluebird Bio common stock on September 30, 2024, through restricted stock units vesting over three years.

Summary

• On September 30, 2024, Michael Cloonan, a director of bluebird bio, Inc., acquired 37,350 shares of common stock.
• The acquisition was in the form of restricted stock units.
• These restricted stock units vest ratably over three years in annual installments, starting on June 20, 2024.
• Following the transaction, Mr. Cloonan beneficially owns 37,350 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects a standard transaction of stock options vesting. It doesn't inherently indicate positive or negative sentiment towards the company.

Positives

• The acquisition of shares by a director may signal confidence in the company's future prospects.

Future Outlook

The restricted stock units will continue to vest over the next three years, potentially increasing Mr. Cloonan's holdings.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates